UnitedHealth Rallies on Cost Control as Elevance Health Sinks on Margin Fears

UnitedHealth Group and Elevance Health reported starkly different market reactions to their latest quarterly earnings, highlighting investor focus on underlying profitability trends over headline numbers. While both managed care giants beat earnings-per-share estimates, UnitedHealth's stock gained 1.8% on signs of improving cost control, whereas Elevance Health's shares plummeted 12.6% amid concerns about shrinking margins.

UnitedHealth's Margin Turnaround Boosts Shares

The key driver for UnitedHealth was a significant improvement in its Medical Care Ratio (MCR), which measures the portion of premiums paid out for medical claims. The company's MCR fell to 86.7% in the second quarter, down from 89.4% a year ago and below analyst expectations of 88.6%. This improvement in profitability underpinned a 31.6% EPS surprise.

Following the strong results, UnitedHealth raised its full-year 2026 adjusted EPS guidance to a range of $19.50–$20.00. The performance prompted positive analyst revisions, with Bernstein raising its price target to $512 and Mizuho increasing its 2026–2028 EPS estimates, according to Investing.com.

Elevance Punished for Margin Compression

In contrast, Elevance Health's stock fell sharply despite posting a nearly 20% beat on quarterly EPS and raising its annual guidance. The market looked past the headline figures to focus on deteriorating profitability. The company's operating margin fell from 4.9% to 3.5% year-over-year, driven by a rising Benefit Expense Ratio, which climbed 80 basis points to 89.7%.

Ad

Elevance attributed the pressure to elevated medical cost trends, particularly in its Medicaid and Government segments. The company also reported a sequential membership decline of 469,000. The negative sentiment was reflected in analyst consensus, with 30-day EPS revisions turning negative by 8.3%, signaling skepticism about the company's cost trajectory.

Quality Momentum vs. Value Play

The divergent results frame a classic quality-versus-value debate for investors. UnitedHealth is demonstrating strong fundamental momentum with improving margins and a diversified earnings stream from its Optum segment. Its stock is currently seen as having a 19.1% upside to its fair value of $506, per Investing.com data.

Elevance, however, presents a value case. The stock now trades at a significant discount to its peer, with a forward price-to-earnings ratio of 14.2x compared to UnitedHealth's 21.7x. It also offers a higher free cash flow yield and stronger liquidity. Analysts see a potential 18.5% upside, with Guggenheim calling the selloff "overblown," suggesting the market may have overreacted to the near-term cost pressures.